BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology

blonca9
Nov 5, 2024
1 min read

Executive Chairman Alexander Gebauer describes this approach to aiming to prevent toxic amyloid beta clumps from developing in the first place, and why Galimedix has focused on conditions like dry AMD and glaucoma a little ahead of its Alzheimer's program.

Brought to you by

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

BIO-Europe: Galimedix is developing amyloid beta aggregation modulators to try to block toxic Aβ upstream of where most others have focused - the lead programs are in ophthalmology

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight